McKesson Corporation (MCK) - Q2 2025 10-Q Summary
Business Context and Reporting Period
This summary covers the quarterly period ended September 30, 2024 (Fiscal Q2 2025). McKesson Corporation is a diversified healthcare services leader operating in four segments: U.S. Pharmaceutical, Prescription Technology Solutions (RxTS), Medical-Surgical Solutions, and International. The company reported a significant decline in net income compared to the prior year, primarily driven by non-cash charges related to the divestiture of its Canadian retail business and restructuring initiatives.
Key Financial Metrics
| Metric | Q2 2025 (3 Months) | Q2 2024 (3 Months) | YTD 2025 (6 Months) | YTD 2024 (6 Months) |
|---|---|---|---|---|
| Revenues | $93,651 million | $77,215 million | $172,934 million | $151,698 million |
| Gross Profit | $3,248 million | $3,069 million | $6,400 million | $6,091 million |
| Operating Income | $578 million | $951 million | $1,607 million | $2,051 million |
| Net Income (Attributable to MCK) | $241 million | $664 million | $1,156 million | $1,622 million |
| Diluted EPS | $1.87 | $4.92 | $8.89 | $11.95 |
| Cash from Operations (YTD) | $720 million | ($87 million) | $720 million | ($87 million) |
| Total Debt | $5.74 billion | $5.63 billion | $5.74 billion | $5.63 billion |
| Cash & Equivalents | $2.51 billion | $4.58 billion | $2.51 billion | $4.58 billion |
Material Changes vs. Prior Period
- Revenue Growth: Revenues increased 21% year-over-year (YoY) for the quarter and 14% YoY for the six months, driven by market growth in the U.S. Pharmaceutical segment (higher volumes and specialty drugs) and the International segment.
- Profitability Decline: Net income attributable to McKesson dropped 64% for the quarter and 29% for the six months. This was primarily due to a $643 million non-cash charge to remeasure the Canadian retail disposal group (Rexall and Well.ca) to fair value less costs to sell.
- Restructuring Charges: The company recorded $171 million in restructuring charges for the quarter and $181 million for the six months, related to enterprise-wide initiatives to modernize technology and reduce costs. Total anticipated charges for these initiatives are $650 million to $700 million.
- Effective Tax Rate: The reported income tax rate spiked to 46.3% for the quarter (vs. 23.3% prior year) due to the non-deductible nature of the Canadian disposal group remeasurement charge.
- Rite Aid Recovery: A $203 million credit was recorded related to the reassessment of bad debt reserves for Rite Aid following its emergence from bankruptcy, partially offsetting operating expenses.
Guidance, Outlook, and Risks
- Canadian Divestiture: The sale of the Canadian retail disposal group is expected to close in the second half of fiscal 2025, subject to regulatory approvals. The transaction includes an adjusted purchase price of approximately $148 million.
- Acquisition: McKesson announced a definitive agreement to acquire a 70% controlling interest in Core Ventures for approximately $2.49 billion. The transaction is subject to regulatory clearance, including a request for additional information from the FTC.
- Capital Allocation: The company returned $2.2 billion to shareholders in the first half of fiscal 2025 via $2.0 billion in share repurchases and $162 million in dividends. The Board increased the quarterly dividend to $0.71 per share and authorized an additional $4.0 billion for share repurchases ($8.6 billion remaining).
- Opioid Litigation: Total estimated liability for opioid-related claims stands at $6.4 billion. The company recorded a $108 million charge for the six months related to estimated liabilities for proposed settlements with hospitals and third-party payors.
- Restructuring Outlook: Enterprise-wide restructuring programs are anticipated to be substantially complete by fiscal 2028.
Investor Verification Checklist
- Canadian Sale Timing: Verify the status of regulatory approvals for the Rexall/Well.ca divestiture and the expected closing date in fiscal 2025.
- Restructuring Execution: Monitor the progress of the $650-$700 million restructuring initiative and its impact on future operating margins.
- Opioid Liability Accruals: Track updates on the $6.4 billion opioid litigation liability, specifically regarding the proposed settlements with acute care hospitals and third-party payors.
- Core Ventures Acquisition: Assess the regulatory review status of the Core Ventures acquisition and potential impacts on the U.S. Pharmaceutical segment.
- Working Capital Trends: Review the significant increase in accounts payable ($6.2 billion increase YTD) and receivables ($3.5 billion increase YTD) to ensure cash flow stability.